0000000000452640
AUTHOR
Beatriz Fernandez-fernandez
Research update for articles published in EJCI in 2016
The association of an excessive blood pressure increase with exercise (i.e., an increase in systolic blood pressure with exercise ≥95th percentile) with lower risk of subsequent events in patients with known or suspected coronary artery disease has been consistently verified even in those with baseline hypertension. Nonetheless, this negative association, also confirmed in another study on a Japanese population, might depend on peak VO2, such that the prognostic value of blood pressure response might be limited in patients with preserved exercise capacity. In addition, a hypertensive response with exercise (defined as a systolic blood pressure ≥220 mmHg during the test) has also been associ…
Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
Hospital admissions and mortality from the Coronavirus disease 2019 (COVID-19) pandemic are spreading throughout the world, and second and third waves are thought to be likely. Risk factors for severe COVID-19 include diabetes, chronic kidney disease and cardiovascular disease. Currently, there is no vaccine and no approved therapy. Therapeutic approaches are aimed at preventing viral replication and spread, limiting the impact of the inflammatory overdrive (cytokine storm), preventing thromboembolic complications and replacing or supporting organ function. However, despite organ support, mortality is currently 65% for those receiving advanced respiratory support and 78% for those requiring…
SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
Abstract Sodium–glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluationtrial. More recently, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial showed that dapagliflozin improved CV outcomes in patients with HF with or without diabetes. Protection from HF in non-diabetics was confirmed for empagliflozin in the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Fa…